JUSTINA THOMAS: Open Payments
NPI 1487351748 · BEAUMONT, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,776 in 207 payments from 11 companies in 2025. Trend: 2023 $429 · 2024 $1,979 · 2025 $3,776
Food & beverage: $3,764Education: $12
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 34 | $627 |
| Teva Pharmaceuticals USA, Inc. | 40 | $603 |
| Neurocrine BioSciences, Inc. | 27 | $603 |
| ABBVIE INC. | 31 | $519 |
| Janssen Pharmaceuticals, Inc | 23 | $499 |
| Vanda Pharmaceuticals Inc. | 17 | $272 |
| E.R. Squibb & Sons, L.L.C. | 13 | $203 |
| Lundbeck LLC | 10 | $196 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $131 |
| Alkermes, Inc. | 5 | $105 |
Products named: REXULTI, INGREZZA, VRAYLAR, INVEGA SUSTENNA, AUSTEDO XR, UZEDY, COBENFY, FANAPT.
Industry payments across CA — which companies pay providers there.
